¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"canine virus hepatitis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • helper virus
    º¸Á¶¹ÙÀÌ·¯½º
  • hemadsorption virus
    Ç÷±¸ÈíÂø¹ÙÀÌ·¯½º
  • herpes simplex virus
    ´Ü¼øÇ츣Æä½º¹ÙÀÌ·¯½º
  • human immunodeficiency virus
    »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • human immunodeficiency virus-2
    »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º2
  • human papilloma virus
    »ç¶÷À¯µÎÁ¾¹ÙÀÌ·¯½º
  • human papilloma virus test
    »ç¶÷À¯µÎÁ¾¹ÙÀÌ·¯½º°Ë»ç
  • human T-cell lymphoma/leukemic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁÁ¾/¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T-cell lymphotropic virus
    »ç¶÷T¼¼Æ÷¸²ÇÁģȭ¹ÙÀÌ·¯½º
  • influenza virus
    ÀÎÇ÷翣ÀÚ¹ÙÀÌ·¯½º
  • Japanese B encephalitis virus
    ÀϺ»BÇü³ú¿°¹ÙÀÌ·¯½º
  • Korean hemorrhagic fever virus
    Çѱ¹ÇüÃâÇ÷¿­¹ÙÀÌ·¯½º
  • Marburg virus disease
    ¸¶¸£ºÎ¸£Å©¹ÙÀÌ·¯½ºº´
  • masked virus
    ÀºÆó¹ÙÀÌ·¯½º
  • measles virus
    È«¿ª¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • hepatitis D
    µðÇü°£¿°
  • halothane hepatitis
    ÇÒ·Îź°£¿°
  • hepatitis carrier state
    °£¿°º¸±ÕÀÚ»óÅÂ
  • infantile hepatitis
    ¿µ¾Æ°£¿°
  • infectious hepatitis
    Àü¿°°£¿°, ¿¡ÀÌÇü°£¿°
  • lupus hepatitis
    ·çǪ½º°£¿°
  • milkborne infectious hepatitis
    ¿ìÀ¯Àü¿°°£¿°
  • neonatal hepatitis
    ½Å»ý¾Æ°£¿°
  • non-A, non-B hepatitis
    ¿¡À̺ñÀ̿ܰ£¿°
  • post-transfusion hepatitis
    ¼öÇ÷Èİ£¿°
  • serum hepatitis
    Ç÷û°£¿°
  • suppurative hepatitis
    È­³ó°£¿°
  • toxic hepatitis
    µ¶¼º°£¿°
  • toxipathic hepatitis
    µ¶¹°¼º°£¿°
  • transfusion hepatitis
    (¢¡post-transfusion hepatitis) ¼öÇ÷Èİ£¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Aedes iridescent virus
    ½£¸ð±â ¹«Áö°³ ¹ÙÀÌ·¯½º
  • African horse sickness virus
    ¾ÆÇÁ¸®Ä« ¸»º´¹ÙÀÌ·¯½º
  • African swine fever virus
    ¾ÆÇÁ¸®Ä« µÅÁö¿­¹ÙÀÌ·¯½º
  • Aleutian mink disease virus
    ¾Ë·ù»ê¹ÖÅ©º´ ¹ÙÀÌ·¯½º
  • Aujeszkys disease virus
    ¿ÀÁ¦½ºÅ°º´¹ÙÀÌ·¯½º
  • B Virus
    B¹ÙÀÌ·¯½º
  • B type virus particle
    BÇü ¹ÙÀÌ·¯½ºÀÔÀÚ.
  • B type virus particle
    BÇü ¹ÙÀÌ·¯½ºÀÔÀÚ.
  • BK virus
    BK¹ÙÀÌ·¯½º
  • BK virus
    BK ¹ÙÀÌ·¯½º
  • Bittner virus
    ºñÆ®³Ê¹ÙÀÌ·¯½º, cf.MMTV
  • Bittners virus
    ºñÆ®³Ê¹ÙÀÌ·¯½º, cf.MMTV
  • Bunyamwera virus
    ºÐ¾ä¿þ¶ó¹ÙÀÌ·¯½º? 79
  • C-type virus particle
    CÇü ¹ÙÀÌ·¯½ºÀÔÀÚ.
  • Chikungunya virus
    Ä¡Äﱸ´Ï¾ß ¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • epizootic hepatitis
    µ¿¹°À¯Ç༺ °£¿°.
  • fulminant hepatitis
    Àü°Ý¼º °£¿°
  • fulminant hepatitis
    Àü°Ý¼º °£¿°.
  • fulminant hepatitis
    Àü°Ý¼º°£¿°(¡­ÊÜæú)
  • fulminating hepatitis
    Àü°Ý¼º °£¿°.
  • granulomatous hepatitis
    À°¾ÆÁ¾¼º °£¿°.
  • gummatous hepatitis
    °í¹«Á¾¼º °£¿°.
  • hemorrhagic hepatitis
    ÃâÇ÷(¼º) °£¿°.
  • hepatitis
    °£¿°(ÊÜæú).
  • hepatitis B core antigen (HBc Ag)
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen (HBs Ag)
    BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
  • hepatitis B surface antigen(HBs Ag)
    BÇü °£¿°Ç¥¸éÇ׿ø
  • hepatitis D coinfection
    D Çü °£¿°µ¿½Ã°¨¿°
  • hepatitis a
    AÇü°£¿°(¡­ÊÜæú)
  • hepatitis b
    BÇü°£¿°(¡­ÊÜæú)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MDCK Madin-Darby canine kidney
ALV Abelson leukemia virus; adeno-like virus; alveolar, alveolus; ascending lumbar vein; avian leukosis ...
RV random variable; rat virus; Rauscher virus; rectovaginal; reinforcement value; renal vein; residual ...
SV saphenous vein; sarcoma virus; satellite virus; selective vagotomy; semilunar valve; seminal vesicle...
HAV Hepatitis A Virus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
anti-HCV Antibodies against hepatitis C virus
anti-HAV Antibodies to hepatitis A virus
anti-HCV Antibodies to hepatitis C virus
Anti-HCV Antibodies to the Hepatitis C virus
Anti-HCV Antibody to Hepatitis C Virus
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • herpes simplex virus
    ´Ü¼ø Æ÷Áø ¹ÙÀÌ·¯½º
  • herpes simplex virus type 1
    Á¦1Çü ´Ü¼ø Æ÷Áø ¹ÙÀÌ·¯½º
  • herpes virus
    Æ÷Áø ¹ÙÀÌ·¯½º, Ç츣Æä½º ¹ÙÀÌ·¯½º
    1. DNA ¹ÙÀÌ·¯½º Áß Å« ±×·ì¿¡ ¼ÓÇÏ¸ç ´ëºÎºÐÀÇ µ¿¹°¿¡¼­ ºÐ¸®µÈ´Ù. nucleoca
  • herpes zoster virus
    ¼öµÎ ´ë»ó Æ÷Áø ¹ÙÀÌ·¯½º, ´ë»ó Æ÷Áø ¹ÙÀÌ·¯½º
    1. °¨¿° ½Ã ³ú ½Å°æÀý, ô¼ö ÈıÙÀÇ ½Å°æÀý ¹× ¸»ÃʽŰæÀÇ ±Þ¼º ¿°Áõ¼º ÁúȯÀ» ¹ß»ý½ÃŰ¸ç ¸»ÃʽŰæ Áö¹è ¿µ¿ª¿¡ ÀÏÄ¡ÇÏ¿© ´ë»ó ¼öÆ÷¸¦ º¼ ¼ö ÀÖÀ¸¸ç µ¿ ºÎÀ§ÀÇ ½Å°æÅëÀ» ¾ß±âÇÑ´Ù. 2. ¾ËÆÄ Ç츣Æä½º ¹ÙÀÌ·¯½º·Î¼­ ÁÖ·Î Á¡¸·, ÇǺÎ, ½Å°æ µîÀ» ħ¹ü. ¹è½Å°æ±ÙÀýÀÇ ½Å°æ¿ø ÁÖÀ§ ¼¼Æ÷¿¡ Àáº¹ÇØ ÀÖ´Ù°¡ ¼ö³â ÈÄ ÀçȰ¼ºÈ­ÇÑ´Ù. ¼öµÎ¿Í ´ë»ó Æ÷ÁøÀ» ÀÏÀ¸Å²´Ù.
  • human immunodeficiency virus
    Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º
  • human immunodeficiency virus infection
    Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º °¨¿°
  • human papilloma virus
    ÀÎü À¯µÎÁ¾ ¹ÙÀÌ·¯½º
    ÀÎü Áúȯ°ú µ¿¹° Áúȯ°úÀÇ À¯»çÁ¡Àº ¸Å¿ì ³î¶ø´Ù. ÇǺÎÀÇ ÆíÆò »óÇÇ ¼¼Æ÷¿¡ ´ëÇÑ ÇöÀúÇÑ Ä£È­¼ºÀ» º¸ÀδÙ. µ¿¹°¿¡¼­ À¯µÎÁ¾ ¹ÙÀÌ·¯½º´Â ÆíÆò »óÇÇ¿¡ ¾ç¼º À¯µÎÁ¾, ÀåÀÇ ¼± »óÇÇ¿¡ ¼±Á¾, ¹æ±¤¿¡ À¯µÎÁ¾À» ÀÏÀ¸Å°¸ç »ó´çÇÑ ¼ö°¡ ¾Ç¼ºÀ¸·Î ÁøÇàµÈ´Ù. »ç¶÷¿¡¼­µµ ÈĵÎÀÇ À¯µÎÁ¾, ¿ÜÀ½, À½°æ, Ç×¹® ÁÖº¯ºÎ¿¡ ÷±Ô Äܵô·Ò
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human t-cell leukemia virus
    ÀÎü T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • Japanese encephalitis virus
    ÀϺ» ³ú¿° ¹ÙÀÌ·¯½º
    ÀϺ» ³ú¿°ÀÇ º´¿øÃ¼. 1934³â¿¡ ÇϾ߽ð¡ ³ú³» Á¢Á¾¹ý¿¡ ÀÇÇØ óÀ½ ¿ø¼þÀÌ¿¡°Ô ÀüÆÄÇϰí, 36³â¿¡´Â ´Ù´Ï±¸Ä¡, °¡»çÇ϶ó µîÀÌ ½ÇÇè¿ë Á㸦 ÀÌ¿ëÇÏ¿© ºÐ¸®¿¡ ¼º°øÇÏ¿´´Ù. Å©±â´Â 15¡­30 mÀÌ°í ¼¼ÀÎÆ®·çÀ̽º ³ú¿°À̳ª ¼­ ³ªÀÏ ³ú¿°ÀÇ ¹ÙÀÌ·¯½º¿Í ºñ½ÁÇѵ¥, º´µ¶ÀÇ ÁßÈ­ ½ÃÇèÀ¸·Î ±¸º°ÇÑ´Ù. ¸ð±â°¡ ¸Å°³ÇÏ¿© »ç¶÷°ú °¡Ãà¿¡ °¨¿°µÇ´Âµ¥, ¸ð±â°¡ ¾ø´Â µ¿°è¸¦ ¾î¶»°Ô ³Ñ±â°í ´ÙÀ½ÇØ¿¡ ´Ù½Ã À¯ÇàÇÏ´ÂÁö ÆÇ¸íµÇ¸é ¿¹¹æ ´ëÃ¥ÀÌ È®¸³µÇ´Â °ÍÀ̳ª ¾ÆÁ÷ ¹àÇôÁöÁö ¾Ê°í ÀÖ´Ù. ¿Â´ëÁö¹æ¿¡¼­´Â µ¿¸éÇÑ ¸ð±âÀÇ Ã¼³»¿¡¼­ ÇØ¸¦ ³Ñ±æ °¡´É¼ºµµ ÀÖÀ¸³ª ¾ÆÁ÷ ÀÔÁõµÇÁö ¾Ê¾Ò°í, ¸ð±â¸¦ Àâ¾Æ¸Ô´Â µµ¸¶¹ìÀ̳ª µµ¸¶¹ìºÙÀÌÀÇ Ã¼³»¿¡¼­ ÇØ¸¦ ³Ñ±æ °¡´É¼ºÀ̳ª, µÕÁö¸¦ ¶°³¯ ¼ö ¾ø´Â µé»õ, ƯÈ÷ ±îÄ¡·ùÀÇ Ã¼³»¿¡¼­ »ì¾Æ³²´Â´Ù´Â °ßÇØµµ ÀÖ´Ù. ÇÑÆí °¨¿°µÈ ¸»À̳ª µÅÁö´Â ±× ÇØÀÇ ¹ÙÀÌ·¯½º¸¦ ¼ºÀå½Ãų ¼ö´Â ÀÖÀ¸³ª ¹ÙÀÌ·¯½ºÀÇ º¸À¯ µ¿¹°Àº ¾Æ´Ï¶ó°í ÇÑ´Ù.
  • Lassa fever virus
    ¶ó»ç ¿­ ¹ÙÀÌ·¯½º
    ¾Æ·¹³ª ¹ÙÀÌ·¯½º°ú¿¡ ¼ÓÇÏ¸ç ¼­¾ÆÇÁ¸®Ä«¿¡ »ç´Â ¾ÆÇÁ¸®Ä« ÁýÁã »çÀÌ¿¡ Áö¼Ó °¨¿°µÇ°í ÀÖÀ¸¸ç »ç¶÷¿¡ ´ëÇÑ °¨¿°Àº Ÿ¾×À̳ª ´¢Áß¿¡ ¹è¼³µÈ ¹ÙÀÌ·¯½º¿¡ ¿À¿°µÈ À½½Ä¹°À̳ª ½Ä±â¸¦ ÅëÇØ¼­ ÀϾ´Ù.
  • lymphadenopathy virus
    ¸²ÇÁÀýÁõ ¹ÙÀÌ·¯½º
  • lymphocystis virus
    ÀÓÆÄ ³¶Á¾ ¹ÙÀÌ·¯½º
  • measles virus
    È«¿ª ¹ÙÀÌ·¯½º
    ÆÄ¶ó ¹Í¼Ò ¹ÙÀÌ·¯½ºÀÇ ÀϹÝÀû ¼º»óÀ» Áö´Ñ º´¿øÃ¼·Î, »ç¶÷°ú ¿ø¼þÀÌ¿¡ º´¿ø¼ºÀ» ³ªÅ¸³½´Ù. RNA ¹ÙÀÌ·¯½º·Î 56¡É¿¡¼­ 30ºÐ °¡¿­ÇÏ¸é ºÒȰ¼ºÈ­µÈ´Ù. È«¿ª ȯÀÚÀÇ Ä§, °¡·¡, ¿ÀÁÜ¿¡ ÀÖ´Ù. È«¿ª ¹ÙÀÌ·¯½º°¡ Á¸ÀçÇÏ¸é ¸²ÇÁ±¸ Áõ°¡¿Í ¹éÇ÷±¸ °¨¼Ò°¡ º¸ÀÌ°í ¸²ÇÁÀý, Æíµµ¼± µî¿¡´Â ´ÙÇÙ ¼¼Æ÷°¡ ³ªÅ¸³­´Ù
  • monkey pox virus
    ¿ø¼þÀÌ Æø½º ¹ÙÀÌ·¯½º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
vaccination, hepatitis b Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. Vaccination, hepatitis b: hepatits b (hep b) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
vaccination, infectious hepatitis See Vaccination, hepatitis a.
(12 Dec 1998)
vaccineation, serum hepatitis See Vaccination, hepatitis b.
(12 Dec 1998)
giant cell hepatitis Hepatitis in the neonatal period presumed to be due to a variety of causes, chiefly viral; characterised by direct and indirect bilirubinaemia, hepatocellular degeneration, and appearance of multinucleated giant cells; may be difficult to distinguish from biliary atresia, but is more likely to end with recovery, although cirrhosis may develop.
Synonym: giant cell hepatitis.
(05 Mar 2000)
viral hepatitis Liver inflammation caused by viruses. Specific hepatitis viruses have been labelled a, b, c, d, e, f, and g. While other viruses can also cause hepatitis, their primary target is not the liver.
(12 Dec 1998)
viral hepatitis type A A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom.
Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis.
(05 Mar 2000)
viral hepatitis type B A virus disease with a long incubation period (usually 50 to 160 days), caused by hepatitis B virus, a DNA virus and member of the family Hepadnoviridae, usually transmitted by injection of infected blood or blood derivatives or by use of contaminated needles, lancets, or other instruments; clinically and pathologically similar to viral hepatitis type A, but there is no cross-protective immunity; HBsAg is found in the serum and the hepatitis delta virus occurs in some patients.
Synonym: hepatitis B, serum hepatitis, transfusion hepatitis, virus B hepatitis.
(05 Mar 2000)
viral hepatitis type C Principal cause of non-A, non-B posttransfusion hepatitis caused by an RNA virus that may be related to Flaviviridae family.
Synonym: hepatitis C, virus C hepatitis.
(05 Mar 2000)
viral hepatitis type D Acute or chronic hepatitis caused by the hepatitis delta virus, a defective RNA virus requiring HBV for replication. The acute type occurs in two forms: 1) coinfection, the simultaneous occurrence of hepatitis B virus and hepatitis delta virus infections, which usually is self-limiting; 2) superinfection, the appearance of hepatitis delta virus infection in a hepatitis B virus carrier, which often leads to chronic hepatitis The chronic type appears to be more severe than other types of viral hepatitis.
Synonym: delta hepatitis, hepatitis D.
(05 Mar 2000)
viral hepatitis type E Hepatitis caused by a nonenveloped, single-stranded, positive-sense RNA virus 27-34 nm in diameter, unrelated to other hepatitis; it is the principal cause of enterically transmitted, waterborne, epidemic NANB hepatitis occurring primarily in Asia and Africa.
Synonym: hepatitis E.
(05 Mar 2000)
viral hepatitis vaccines Any vaccine raised against any virus or viral derivative that causes hepatitis.
(12 Dec 1998)
peliosis hepatitis A rare condition in which the liver contains very numerous small blood-filled spaces, sometimes lined with endothelium; it may be found incidentally or rupture may cause intraperitoneal haemorrhage.
(05 Mar 2000)
goose viral hepatitis An acute, highly fatal disease of goslings and Muscovy ducklings caused by the goose parvovirus and characterised by anorexia, feather loss, and tissue haemorrhages.
Synonym: Derzsy's disease.
(05 Mar 2000)
persistent chronic hepatitis A benign chronic hepatitis that may follow acute viral hepatitis A or B, or complicate bowel diseases; after six months, liver biopsy changes are mild, unlike active chronic hepatitis; rarely, if ever, progresses to cirrhosis, portal hypertension, or liver failure.
(05 Mar 2000)
cholangiolitic hepatitis Hepatitis with inflammatory changes around small bile ducts, producing mainly obstructive jaundice; may be due to viral infection or bacterial infection ascending biliary tree because of obstruction.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á